The pattern of gene expression and gene dose profiles of 6-Mercaptopurine- and 6-Thioguanine-resistant human leukemia cells

Biochemical and Biophysical Research Communications

Volumn 411, Issue 1, 2011, Pages 156-161

  Karim, Hazhar ^a   Hashemi, Jamileh ^a   Larsson, Catharina ^a   Moshfegh, Ali ^a   Fotoohi, Alan K ^a   Albertioni, Freidoun ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

6 Mercaptopurine; 6 Thioguanine; Comparative genomic hybridization; Leukemia; Microarray; Resistance

Indexed keywords

ADENYLATE KINASE; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3; DNA; DNA POLYMERASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; MERCAPTOPURINE; MESSENGER RNA; RNA; TIOGUANINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DNA NUCLEOTIDYLEXOTRANSFERASE; DRUG RESISTANCE, NEOPLASM; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THIOGUANINE;

EID: 79960563099     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.120     Document Type: Article

References (18)

1. Elgemeie G.H. Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites. Current Pharmaceutical Design 2003, 9:2627-2642.
2. Fotoohi A.K., Coulthard S.A., Albertioni F. Thiopurines: factors influencing toxicity and response. Biochemical Pharmacology 2010, 79:1211-1220.
3. Karas-Kuzelicki N., Mlinaric-Rascan I. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond. Pharmacogenomics 2009, 10:1309-1322.
4. Stocco G., Crews K.R., Evans W.E. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert opinion on drug delivery 2010, 9:23-37.
5. Lennard L. The clinical pharmacology of 6-Mercaptopurine. European Journal of Clinical Pharmacology 1992, 43:329-339.
6. Coulthard S.A., Hogarth L.A., Little M., Matheson E.C., Redfern C.P., Minto L., Hall A.G. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Molecular Pharmacology 2002, 62:102-109.
7. Fotoohi A.K., Lindqvist M., Peterson C., Albertioni F. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochemical and Biophysical Research Communications 2006, 343:208-215.
8. Hannelius U., Gherman L., Makela V.V., Lindstedt A., Zucchelli M., Lagerberg C., Tybring G., Kere J., Lindgren C.M. Large-scale zygosity testing using single nucleotide polymorphisms. Twin research and human genetics 2007, 10:604-625.
9. Fotoohi A.K., Assaraf Y.G., Moshfegh A., Hashemi J., Jansen G., Peters G.J., Larsson C., Albertioni F. Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochemical Pharmacology 2009, 77:1410-1417.
10. Hashemi J., Worrall C., Vasilcanu D., Fryknas M., Sulaiman L., Karimi M., Weng W.H., Lui W.O., Rudduck C., Axelson M., Jernberg-Wiklund H., Girnita L., Larsson O., Larsson C. Molecular Characterization of Acquired Tolerance of Tumor Cells to Picropodophyllin (PPP). PLoS ONE 2011, 6:e14757.
11. L.H. Saal, C. Troein, J. Vallon-Christersson, S. Gruvberger, A. Borg, and C. Peterson, BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data, Genome Biology 3 (2002) SOFTWARE0003.
12. Yang M.C., Ruan Q.G., Yang J.J., Eckenrode S., Wu S., McIndoe R.A., She J.X. A statistical method for flagging weak spots improves normalization and ratio estimates in microarrays. Physiological genomics 2001, 7:45-53.
13. Autio R., Hautaniemi S., Kauraniemi P., Yli-Harja O., Astola J., Wolf M., Kallioniemi A. CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics 2003, 19:1714-1715.
14. Sahai Srivastava B.I., Minowada J. Terminal deoxynucleotidyl transferase activity in a cell line (molt-4) derived from the peripheral blood of a patient with acute lymphoblastic leukemia. Biochemical and Biophysical Research Communications 1973, 51:529-535.
15. Onciu M., Lorsbach R.B., Henry E.C., Behm F.G. Terminal deoxynucleotidyl transferase-positive lymphoid cells in reactive lymph nodes from children with malignant tumors: incidence, distribution pattern, and immunophenotype in 26 patients. American Journal of Clinical Pathology 2002, 118:248-254.
16. Liu L., McGavran L., Lovell M.A., Wei Q., Jamieson B.A., Williams S.A., Dirks N.N., Danielson M.S., Dubie L.M., Liang X. Nonpositive terminal deoxynucleotidyl transferase in pediatric precursor B-lymphoblastic leukemia. American Journal of Clinical Pathology 2004, 121:810-815.
17. Di Santo R., Maga G. Human terminal deoxynucleotidyl transferases as novel targets for anticancer chemotherapy. Current Medicinal Chemistry 2006, 13:2353-2368.
18. Noma T., Fujisawa K., Yamashiro Y., Shinohara M., Nakazawa A., Gondo T., Ishihara T., Yoshinobu K. Structure and expression of human mitochondrial adenylate kinase targeted to the mitochondrial matrix. Biochemical Journal 2001, 358:225-232.